AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19231545 — intervention group
Group type: EXPERIMENTAL
Intervention: Real interferential therapy (IFT) sessions, 12 sessions over a 4-week period.
Number of subjects: 26
Study 19231545 — intervention group
Group type: COMPARATOR
Intervention: Placebo IFT sessions, 12 sessions over a 4-week period.
Number of subjects: 26
Study 17551146 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry-derived proteomic signature of 25 signals
Number of subjects: 58
Study 15179026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (0.85 mg DMT/kg body weight)
Number of subjects: 18
Study 15179026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15179026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 18
Study 11296131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies of purine analogues (pentostatin, fludarabine, cladribine) and monoclonal antibodies (rituximab, CAMPATH I‐H)
Number of subjects: 0
Study 11296131 — intervention group
Group type: COMPARATOR
Intervention: Single-agent therapy
Number of subjects: 0
Study 11296131 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies designed to induce high-quality responses
Number of subjects: 0
Study 9496710 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n=6)
Number of subjects: 16
Study 9496710 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with end-stage heart failure (n=10)
Number of subjects: 16
Study 9496710 — intervention group
Group type: EXPERIMENTAL
Intervention: Net extraction of NOx across the heart
Number of subjects: 16
Study 8044980 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% flurbiprofen sodium ophthalmic solution
Number of subjects: 105
Study 8044980 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 105
Study 3058657 — intervention group
Group type: EXPERIMENTAL
Intervention: 60.0 Gy
Number of subjects: 50
Study 3058657 — intervention group
Group type: EXPERIMENTAL
Intervention: 64.8 Gy
Number of subjects: 50
Study 3058657 — intervention group
Group type: EXPERIMENTAL
Intervention: 69.6 Gy
Number of subjects: 50
Study 3058657 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 50
Study 3058657 — intervention group
Group type: COMPARATOR
Intervention: Comparison with RTOG Protocol 71‐04 (60 Gy in 30 fractions in 6 weeks)
Number of subjects: 50
Study 31898512 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT intervention app (SPARX)
Number of subjects: 10000
Study 31898512 — intervention group
Group type: EXPERIMENTAL
Intervention: Second CBT app (Sleep Ninja)
Number of subjects: 10000
Study 31898512 — intervention group
Group type: COMPARATOR
Intervention: Non-active control group
Number of subjects: 10000
Study 30691980 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB booster dose
Number of subjects: 4
Study 30691980 — intervention group
Group type: COMPARATOR
Intervention: 2 catch-up doses of 4CMenB (vaccine-naïve)
Number of subjects: 4
Study 30691980 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (Primed_4y and Primed_7.5y)
Number of subjects: 4
Study 30691980 — intervention group
Group type: COMPARATOR
Intervention: 4CMenB vaccine (Naïve_4y and Naïve_7.5y)
Number of subjects: 4
Study 28072797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150, 300, 600, and flexible 150-600 mg/d)
Number of subjects: 0
Study 28072797 — intervention group
Group type: COMPARATOR
Intervention: Concomitant NeP medications
Number of subjects: 0
Study 28072797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 24853566 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages for medication reminders and education
Number of subjects: 90
Study 24853566 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages for education
Number of subjects: 90
Study 24853566 — intervention group
Group type: COMPARATOR
Intervention: No text messages
Number of subjects: 90
Study 24229729 — intervention group
Group type: EXPERIMENTAL
Intervention: eCases level 2
Number of subjects: 120
Study 24229729 — intervention group
Group type: EXPERIMENTAL
Intervention: eCases level 2+
Number of subjects: 120
Study 24229729 — intervention group
Group type: EXPERIMENTAL
Intervention: eTextbook level 2
Number of subjects: 120
Study 24229729 — intervention group
Group type: EXPERIMENTAL
Intervention: eTextbook level 2+
Number of subjects: 120
Study 21636012 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation of hop rho iso-alpha acids (200 mg), berberine sulfate trihydrate (100 mg), vitamin D₃ (500 IU), and vitamin K₁ (500 μg) twice daily
Number of subjects: 51
Study 21636012 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 51
Study 17651103 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine infusion (10 microg/kg/min)
Number of subjects: 70
Study 16218198 — intervention group
Group type: EXPERIMENTAL
Intervention: Blink Reflex (BR)
Number of subjects: 188
Study 16218198 — intervention group
Group type: COMPARATOR
Intervention: Healthy group (control)
Number of subjects: 188
Study 12045515 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative scoliosis patients (after spine fusion)
Number of subjects: 19
Study 12045515 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative scoliosis patients
Number of subjects: 19
Study 12045515 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control)
Number of subjects: 19
Study 10471456 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg daily)
Number of subjects: 1663
Study 10471456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1663
Study 7598921 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA inserted with cuff partially inflated
Number of subjects: 350
Study 7598921 — intervention group
Group type: COMPARATOR
Intervention: LMA inserted with cuff fully deflated
Number of subjects: 350
Study 2221164 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 23
Study 2221164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 67348 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-case surgery (discharge after 8 hours)
Number of subjects: 0
Study 67348 — intervention group
Group type: COMPARATOR
Intervention: Long-stay surgery (discharge on 5th or 6th day)
Number of subjects: 0
Study 67348 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-case surgery
Number of subjects: 0
Study 30409941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 20
Study 30409941 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine hydrochloride with 1:200,000 adrenaline
Number of subjects: 20
Study 27322670 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit social support
Number of subjects: 58
Study 27322670 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit social support
Number of subjects: 58
Study 27322670 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 58
Study 24843963 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion therapy
Number of subjects: 128
Study 24843963 — intervention group
Group type: COMPARATOR
Intervention: Qianliekang tablets (Control)
Number of subjects: 128
Study 22619605 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Gufoni's manoeuvre
Number of subjects: 87
Study 22619605 — intervention group
Group type: COMPARATOR
Intervention: Gufoni's manoeuvre
Number of subjects: 87
Study 20815194 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal airflow (Flow Wizard, DiagnoselT, Australia)
Number of subjects: 105
Study 20815194 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal airflow (Flow Wizard, DiagnoselT, Australia) + Oximetry (Radical Set, Masimo, USA)
Number of subjects: 105
Study 20815194 — intervention group
Group type: COMPARATOR
Intervention: Oximetry (Radical Set, Masimo, USA)
Number of subjects: 105
Study 18535115 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus methotrexate
Number of subjects: 682
Study 18535115 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 682
Study 18535115 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 682
Study 15673879 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (mild sedation at 0.5 mug/mL)
Number of subjects: 18
Study 15673879 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (moderate sedation at 1.0 mug/mL)
Number of subjects: 18
Study 15673879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study 12669746 — intervention group
Group type: EXPERIMENTAL
Intervention: Preattentive auditory streaming
Number of subjects: 0
Study 12669746 — intervention group
Group type: COMPARATOR
Intervention: Attention-dependent auditory streaming
Number of subjects: 0
Study 11103752 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg once daily for 5 days)
Number of subjects: 9
Study 8873392 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIV‐HAV
Number of subjects: 301
Study 8873392 — intervention group
Group type: COMPARATOR
Intervention: Al‐HAV
Number of subjects: 301
Study 1556366 — intervention group
Group type: EXPERIMENTAL
Intervention: Management system of restraint release using colored pads corresponding to specific hours.
Number of subjects: 63
Study 1556366 — intervention group
Group type: COMPARATOR
Intervention: Baseline monitoring (no intervention).
Number of subjects: 63
Study 1556366 — intervention group
Group type: COMPARATOR
Intervention: Post-intervention monitoring (no intervention).
Number of subjects: 63
Study 3888857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyfedrine (8-24 mg three times a day)
Number of subjects: 14
Study 3888857 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40-80 mg three times a day)
Number of subjects: 14
Study 31723854 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Number of subjects: 24
Study 31723854 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula (NC)
Number of subjects: 24
Study 26062785 — intervention group
Group type: COMPARATOR
Intervention: 10 mg memantine
Number of subjects: 84
Study 26062785 — intervention group
Group type: COMPARATOR
Intervention: 20 mg memantine
Number of subjects: 84
Study 26062785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 24940052 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium fructoborate (CFB) 110 mg twice per day
Number of subjects: 60
Study 24940052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22908089 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest 1100
Number of subjects: 56
Study 22908089 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest 500
Number of subjects: 56
Study 22908089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooneh 500
Number of subjects: 56
Study 22908089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooneh without fluoride
Number of subjects: 56
Study 20606475 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupressure (applied for 4 weeks, three times a week)
Number of subjects: 28
Study 20606475 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupressure
Number of subjects: 28
Study 20606475 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure (applied for 4 weeks, three times a week)
Number of subjects: 28
Study 18070439 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose midazolam sedation
Number of subjects: 50
Study 18070439 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 15681985 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and educational intervention focusing on recurrence of breast cancer, 4 weeks duration, weekly meetings
Number of subjects: 78
Study 15681985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 78
Study 11951158 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training program on cycle ergometers (5 training units weekly at 40 minutes each for a minimum of 22 training units during 4 weeks)
Number of subjects: 125
Study 11951158 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 125
Study 10588463 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg of warfarin daily in combination with 75 mg of aspirin
Number of subjects: 97
Study 10588463 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 97
Study 10588463 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study 8921777 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline total cholesterol (6.11 mmol/L), non-HDL cholesterol (4.72 mmol/L), LDL cholesterol (3.98 mmol/L)
Number of subjects: 4736
Study 8921777 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HDL cholesterol (1.39 mmol/L) and triglycerides (1.62 mmol/L for fasting participants)
Number of subjects: 4736
Study 8921777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting participants with triglycerides < 4.52 mmol/L
Number of subjects: 4736
Study 1495150 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine 1% cream
Number of subjects: 86
Study 1495150 — intervention group
Group type: COMPARATOR
Intervention: Biologically active tripeptide copper complex 0.4% cream
Number of subjects: 86
Study 1495150 — intervention group
Group type: COMPARATOR
Intervention: Inert vehicle placebo
Number of subjects: 86
Study 6386793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 33
Study 6386793 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 33
Study 6386793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30844053 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 20
Study 30844053 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 20
Study 30844053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose plus acarbose
Number of subjects: 20
Study 30844053 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 20
Study 30320654 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse's intentional presence (4 sessions of 30-45 minutes each)
Number of subjects: 80
Study 30320654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intentional presence)
Number of subjects: 80
Study 27060679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 27060679 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU Vitamin D
Number of subjects: 260
Study 27060679 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU Vitamin D
Number of subjects: 260
Study 23184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline albuminuria (defined as an albumin‐to‐creatinine ratio≥30 mg/g)
Number of subjects: 4597
Study 23184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 4597
Study 23184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 4597
Study 23184565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid loss of estimated GFR over the first 2 years of follow‐up
Number of subjects: 4597
Study 21619748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid antigen detection testing (RADT)
Number of subjects: 543
Study 21619748 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care, without RADT)
Number of subjects: 543
Study 21619748 — intervention group
Group type: EXPERIMENTAL
Intervention: RADT
Number of subjects: 543
Study 19502288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral State Monitor (CSM)
Number of subjects: 40
Study 19502288 — intervention group
Group type: COMPARATOR
Intervention: Bispectral Index (BIS)
Number of subjects: 40
Study 16763388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 11
Study 16763388 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone provocation test
Number of subjects: 11
Study 16763388 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight frequent GH sampling
Number of subjects: 11
Study 16763388 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid function tests
Number of subjects: 11
Study 16763388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid profile testing
Number of subjects: 11
Study 16763388 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin testing
Number of subjects: 11
Study 16763388 — intervention group
Group type: EXPERIMENTAL
Intervention: D-xylose absorption test and fecal fat measurement
Number of subjects: 11
Study 15567207 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with co-occurring significant general medical conditions (GMCs)
Number of subjects: 1500
Study 15567207 — intervention group
Group type: COMPARATOR
Intervention: Patients without GMCs
Number of subjects: 1500
Study 11513909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 or 400 mg depending on bodyweight)
Number of subjects: 168
Study 11513909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 9286179 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone plus counseling (low level of support)
Number of subjects: 100
Study 9286179 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone plus more intensive counseling (intermediate level of support)
Number of subjects: 100
Study 9286179 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone plus enhanced counseling, medical, and psychosocial services (high level of support)
Number of subjects: 100
Study 9286179 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone plus enhanced services (high-intensity, high-cost)
Number of subjects: 100
Study 8290452 — intervention group
Group type: EXPERIMENTAL
Intervention: HAD Hand Wash (povidone-iodine alcoholic disinfectant solution)
Number of subjects: 0
Study 8290452 — intervention group
Group type: COMPARATOR
Intervention: Benzalkonium chloride alcoholic lotion
Number of subjects: 0
Study 2949585 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 200‐110 (isradipine)
Number of subjects: 0
Study 2949585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2949585 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 2949585 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 2949585 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 0
Study 2949585 — intervention group
Group type: COMPARATOR
Intervention: HCTZ
Number of subjects: 0
Study 2949585 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 200‐110 (isradipine) + HCTZ
Number of subjects: 0
Study 29624463 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant androgen deprivation therapy (ADT) with bicalutamide and goserelin for 2 years
Number of subjects: 961
Study 29624463 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant androgen deprivation therapy (ADT) plus mitoxantrone and prednisone (MP)
Number of subjects: 961
Study 29624463 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant androgen deprivation therapy (ADT)
Number of subjects: 961
Study 27342046 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Lactobacillus rhamnosus GR‐1 and L reuteri RC‐14 (109 colony‐forming units) administered for 8 weeks
Number of subjects: 320
Study 27342046 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 8 weeks
Number of subjects: 320
Study 23963460 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and ascorbic acid
Number of subjects: 153
Study 23963460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 153
Study 23963460 — intervention group
Group type: COMPARATOR
Intervention: Plain water
Number of subjects: 153
Study 22264372 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy within the first three days from intubation
Number of subjects: 30
Study 22264372 — intervention group
Group type: COMPARATOR
Intervention: Prolonged intubation (and possibly late tracheostomy) between days 7 and 14 from intubation
Number of subjects: 30
Study 22264372 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy
Number of subjects: 30
Study 22264372 — intervention group
Group type: COMPARATOR
Intervention: Prolonged intubation
Number of subjects: 30
Study 20828987 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral Theme Inventory (MTI)
Number of subjects: 0
Study 20828987 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-Moral Reflection Measure--Short Form (SRM--SF)
Number of subjects: 0
Study 20828987 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral Theme Inventory (MTI) and Socio-Moral Reflection Measure--Short Form (SRM--SF)
Number of subjects: 0
Study 20828987 — intervention group
Group type: COMPARATOR
Intervention: Comparison of moral reasoning abilities
Number of subjects: 0
Study 18837655 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 125
Study 18837655 — intervention group
Group type: COMPARATOR
Intervention: Open prostatectomy (OP)
Number of subjects: 125
Study 18837655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PVP and OP)
Number of subjects: 125
Study 19432501 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg plus Amlodipine 5 mg or 10 mg
Number of subjects: 578
Study 19432501 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg plus Amlodipine 10 mg
Number of subjects: 578
Study 19432501 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg plus Amlodipine 10 mg (separate factorial study)
Number of subjects: 578
Study 15784799 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (single dose of vitamin E)
Number of subjects: 54
Study 15784799 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 54
Study 12436823 — intervention group
Group type: EXPERIMENTAL
Intervention: Local delivery of antimicrobial agents
Number of subjects: 0
Study 12436823 — intervention group
Group type: COMPARATOR
Intervention: Systemic antimicrobial agents
Number of subjects: 0
Study 9745150 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LRS) 1,500 ml at 25 ml/min
Number of subjects: 119